This case involves a plaintiff who suffered a massive heart attack when given a medication during a surgical procedure. The plaintiff, a male in his early twenties, was being prepped for surgery when he had an adverse reaction to one of the drugs administered to him for his hemophilia. He suffered a massive heart attack. Because of the heart attack, he now requires twenty-four-hour care. The drug in question did not have a warning for use on hemophiliacs, though a warning was later added.
Question(s) For Expert Witness
Was the warning label (at the time of the surgery) inadequate?
Expert Witness Response E-004483
By examining the label, coupled with an analysis of similar drugs, medical literature, and other relevant materials, I could arrive at a better perspective on the adequacy of the warning label. I am a doctor of pharmacy and I have done extensive consulting with regards to medico-legal cases. I have worked for the FDA and I specialize in the development of drugs and regulatory procedures, including labeling.
About the author
Michael Talve, CEO
Michael Talve stands at the forefront of legal innovation as the CEO and Managing Director of Expert Institute. Under his leadership, the Expert Institute has established itself as a vital player in the legal technology arena, revolutionizing how lawyers connect with world-class experts and access advanced legal technology. Michael's role involves not only steering the company's strategic direction but also ensuring the delivery of unparalleled intelligence and cutting-edge solutions to legal professionals. His work at Expert Institute has been instrumental in enhancing the capabilities of attorneys in case preparation and execution, making a significant impact on the legal industry's approach to expert consultation and technological integration. Michael's vision and execution have positioned the Expert Institute as a key facilitator in the intersection of law and technology.
